EpiCast Report: Migraine – Epidemiology Forecast to 2026

2017-08-10
Price :
Published : Aug-2017
No. of Pages : 30

EpiCast Report: Migraine – Epidemiology Forecast to 2026

Summary

Migraine is typically characterized by recurring headaches and throbbing pain on one side of the head accompanied by nausea, vomiting, or increased sensitivity to light or smell (Bigal and Lipton, 2006). While most migraineurs experience episodic migraines (EM), a small percentage suffers from chronic migraine (CM). Migraines are also classified into migraine with aura (MWA), in which the migraine is accompanied by other sensory symptoms, and migraine without aura (MOA).

In 2016, there were 73,914,635 total prevalent cases of migraine in adults ages 18 years and older in the 7MM. The US had the most cases, with 30,233,942, making up 40.90% of cases in the 7MM. Italy had the second most cases, with 12,231,868 cases, or 16.55% of cases in the 7MM. Spain had the fewest cases, with 2,199,892 cases (2.98% of cases in the 7MM). Italy also had the highest prevalence of migraine, with 23.63% of adult’s ages 18 years and older experiencing migraine in 2016. Spain had the lowest prevalence, at 5.54%.

In the 7MM, the number of total prevalent cases of migraine is expected to grow to 74,543,569 by 2026, at an Annual Growth Rate (AGR) of 0.09%. The US, France, Spain, and the UK are expected to see small increases in the number of total prevalent migraine cases, while Germany, Italy, and Japan are expected to see small decreases. The largest changes are expected in the US (AGR 0.60%) and Japan (AGR negative 0.87%). Since age- and sex-specific prevalence was held constant throughout the forecast period, all changes in the total prevalent cases of migraine are the result of demographic changes.

Our epidemiologists estimate that 1.61% of total migraine cases in the 7MM in 2016 were CM, corresponding to 1,189,614 cases. Due to the lack of country-specific sources, this percentage was applied to all markets.

The report “EpiCast Report: Migraine – Epidemiology Forecast to 2026” provides an overview of the risk factors, comorbidities, and the global and historical trends for migraine in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases (diagnosed and undiagnosed) of migraine segmented by sex and age (for ages 18 years and older) in these markets. This forecast is further segmented by migraine frequency into EM and CM.

Scope

– The Migraine EpiCast Report provides an overview of the risk factors and global trends of migraine in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of migraine segmented by sex and age (for ages 18 years and older) in these markets. This forecast is further segmented by migraine frequency into episodic migraine (EM) and chronic migraine (CM).
– The migraine epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
– The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Migraine EpiCast report will allow you to –
– Develop business strategies by understanding the trends shaping and driving the global migraine market.
– Quantify patient populations in the global migraine market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for migraine therapeutics in each of the markets covered.
– Identify the percentage of migraine prevalent cases by frequency.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

Meningococcal Vaccines – Global Drug Forecast and Market Analysis to 2029

Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2029 Summary Meningococcal disease is an infection caused by Neisseria meningitidis bacteria, and, although relatively rare, is widely feared because of its high mortality rate even in otherwise healthy individuals. Serogroups A, B, C, W, and Y are the most common meningococcal types in the nine major markets (9MM) covered in this report (US, France, Germany, Italy, Spain, UK, Argentina, Brazil, and China), and immunization of high-risk groups such as infants and adolescents provides the best protection against the infection. Immunization with conjugated meningococcal serogroup C (MenC) is routinely recommended for infants in the 5EU and Brazil, and immunization against serogroup ACWY (MenACWY vaccines) is recommended i......
$10995

Invasive Meningococcal Disease – Epidemiology Forecast to 2029

Invasive Meningococcal Disease - Epidemiology Forecast to 2029 Summary Invasive meningococcal disease (IMD) is a life-threatening condition caused by the bacterium Neisseria meningitidis (N. meningitidis). N. meningitidis is an encapsulated gram-negative bacterium that exists without complication in roughly 5-11% of adults and up to 25% of adolescents. However, if the bacterium moves beyond the nasopharynx and invades body tissue, serious illness can arise, usually in the form of meningitis or septicemia. Symptoms of disease can include fever, headache, stiff neck, nausea, photophobia, and fatigue, among others. The bacterium is spread by respiratory droplets through close or prolonged contact with an infected person and is not as contagious as the common cold or flu. In 2019, there wer......
$3995

Ulcerative Colitis – Epidemiology Forecast to 2029

Ulcerative Colitis - Epidemiology Forecast to 2029 Summary Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by chronic inflammation of the large intestine and the rectum. The inflammation occurs only in the innermost layer of the lining of the intestine. In UC, ulcers develop on the surface of the bowel lining; these may bleed and produce mucus. If the inflammation is confined to rectum, it is called proctitis (Crohn's and Colitis Foundation of America, 2014; Crohn's and Colitis UK, 2019). UC can occur at any age, though most people are diagnosed in their mid-thirties. Men and women are equally likely to be affected, but older men are more likely to be diagnosed than older women. GlobalData epidemiologists utilized historical data obtained from peer-reviewed......
$3995

Contract Dose Manufacturing Industry by the Numbers – Composition, Size, Market Share and Outlook – 2020 Edition

Contract Dose Manufacturing Industry by the Numbers - Composition, Size, Market Share and Outlook - 2020 Edition Summary This expert trend report is a comprehensive look at the finished dose contract manufacturing landscape in 2020, including analysis of dose CMO M&A activity, market size and share. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the supply chain that will provide insights for supplier selection and management. This report gives an important expert quantitative analysis on the contract dose manufacturing industry. Findings are based on the industry's most comprehensive database of the dose CMO industry (GlobalData's Pharma Intelligence Center Contract Service Providers Database) this analysis is driven by a ......
$4995

Egypt Healthcare, Regulatory and Reimbursement Landscape – CountryFocus

Egypt Healthcare, Regulatory and Reimbursement Landscape - CountryFocus Summary GlobalData, the industry analysis specialist, has released its latest report, "Egypt Healthcare, Regulatory and Reimbursement Landscape - CountryFocus". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Egypt. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalDa......
$1995

Coronavirus Disease 2019 (COVID-19) Impact on Telemedicine, a Physician Perspective

Coronavirus Disease 2019 (COVID-19) Impact on Telemedicine, a Physician Perspective Summary Telemedicine is the use of electronic communication for the delivery of remote clinical care. It has been recognized as a critical strategy during the ongoing coronavirus disease 2019 (COVID-19) pandemic to limit the risk of person-to-person transmission of the virus as social distancing has become the norm. It is widely anticipated that COVID-19 may be the tipping point for telemedicine as the full potential of the technology is increasingly realized by patients, healthcare systems, and payers. As a result of the pandemic, regulations and policies governing reimbursement and use of telemedicine have changed significantly, leading to expanded access and an unprecedented demand for these services.......
$1495

Greece Healthcare, Regulatory and Reimbursement Landscape – CountryFocus

Greece Healthcare, Regulatory and Reimbursement Landscape - CountryFocus Summary GlobalData, the industry analysis specialist, has released its latest report: "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Greece". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Greece. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by Glob......
$1995

Duchenne Muscular Dystrophy Disease – Global Clinical Trials Review, H2, 2020

Duchenne Muscular Dystrophy Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Duchenne Muscular Dystrophy Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Critical Limb Ischemia Clinical trials scenario. This report provides top line data relating to the clinical trials on Critical Limb Ischemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's propr......
$2500

Gestational Diabetes Disease – Global Clinical Trials Review, H2, 2020

Gestational Diabetes Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Gestational Diabetes Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Gestational Diabetes Clinical trials scenario. This report provides top line data relating to the clinical trials on Gestational Diabetes. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - ......
$2500

Influenzavirus A Infections – Global Clinical Trials Review, H2, 2020

Influenzavirus A Infections - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Influenzavirus A Infections Global Clinical Trials Review, H2, 2020" provides an overview of Influenzavirus A Infections Clinical trials scenario. This report provides top line data relating to the clinical trials on Influenzavirus A Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary d......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy